Circulating Biomarkers to Identify Patients With Resectable Pancreatic Cancer

<span class="paragraphSection">In this issue of the Journal, Killary et al. evaluate a plasma biomarker combination (CA19-9, tissue factor pathway inhibitor [TFPI], and an isoform of tenascin C [TNC-FNIII-B]) for its ability to distinguish patients with early-stage pancreatic cancer from controls (<a href="#djx004-B1" class="reflinks">1</a>). The authors previously reported their initial experience evaluating these biomarkers (<a href="#djx004-B2" class="reflinks">2</a>). The authors’ study design had several strengths, including the use of multiple disease control groups, blinded analysis of samples, and multiple rounds of validation. The authors found their biomarker panel worked best when compared with controls without pancreatitis or diabetes, finding it could distinguish patients with low-stage pancreatic cancer from healthy controls with an accuracy of 82% (compared with 69% for CA19-9 alone, corresponding to 81% sensitivity, 84% specificity).</span>

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2m1nxn8
via IFTTT